Mutant p53: One, No One, and One Hundred Thousand (Q26770576)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Mutant p53: One, No One, and One Hundred Thousand (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Kamil Lisek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Giannino Del Sal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1

Dawid Walerych

0 references

author name string

Kamil Lisek

2

0 references

Giannino Del Sal

3

0 references

language of work or name

English

0 references

publication date

21 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

published in

Frontiers in Oncology

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion

4 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

A Pin1/mutant p53 axis promotes aggressiveness in breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Modulation of the vitamin D3 response by cancer-associated mutant p53

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

New and emerging HDAC inhibitors for cancer treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Small molecule induced reactivation of mutant p53 in cancer cells

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The rebel angel: mutant p53 as the driving oncogene in breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutational landscape and significance across 12 major cancer types

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 reactivation by small molecules makes its way to the clinic.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 in cancer: new functions and therapeutic opportunities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Tumour-associated mutant p53 drives the Warburg effect

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The spectrum of statin therapy in cancer patients: is there a need for further investigation?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

HSP90 inhibitors: current development and potential in cancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53: one name, many proteins

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Allele-specific p53 mutant reactivation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 cooperates with ETS2 to promote etoposide resistance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

TP53 mutations in human cancer: database reassessment and prospects for the next decade

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Characterization of functional domains necessary for mutant p53 gain of function

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant p53 drives invasion by promoting integrin recycling

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

When mutants gain new powers: news from the mutant p53 field.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Geldanamycin prevents nuclear translocation of mutant p53.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Multiple stress signals activate mutant p53 in vivo

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Gain of function mutations in p53.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Geldanamycin selectively destabilizes and conformationally alters mutated p53

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies.

31 May 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Metabolic control of YAP and TAZ by the mevalonate pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

Disarming mutant p53 oncogenic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2015.00289

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685664

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

28 November 2018

1 reference

12 December 2020

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer

1 reference

12 December 2020

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

1 reference

12 December 2020

Different tumor-derived p53 mutants exhibit distinct biological activities

1 reference

12 December 2020

Pharmacological rescue of mutant p53 conformation and function

1 reference

12 December 2020

Identifiers

DOI

10.3389/FONC.2015.00289

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

release_6ajs3247dbd4znjb3y5lnhhsrm

4 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6ajs3247dbd4znjb3y5lnhhsrm

24 November 2022

mapped directly with Wikidata item

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

26734571

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26734571%20AND%20SRC:MED&resulttype=core&format=json